Analysis Tools
hematopoietic system
|
• at 20 weeks
|
|
• at 20 weeks
|
|
• increased myeloid progenitors in the spleen
|
|
• in the spleen
|
|
• in the spleen
|
|
• mice exhibit an increase in the GMP population (including monocyte and granulocyte progenitors) compared with wild-type mice
|
|
• at 20 weeks, progressive in the peripheral blood
|
|
• at 20 weeks
|
|
• at 20 weeks, bone marrow and peripheral lymphoid tissue exhibit myeloid dysplasia (including blasts, promyelocytes, myelocytes, or metamyelocytes) unlike in wild-type mice
|
|
• hematopoietic progenitors exhibit increased serial replating capacity compared with control cells
|
neoplasm
|
• at 20 weeks, mice exhibit chronic myelomonocytic leukemia (CMML)-like phenotype unlike wild-type mice
|
immune system
|
• at 20 weeks
|
|
• at 20 weeks
|
|
• mice exhibit an increase in the GMP population (including monocyte and granulocyte progenitors) compared with wild-type mice
|
|
• at 20 weeks, progressive in the peripheral blood
|
|
• at 20 weeks, bone marrow and peripheral lymphoid tissue exhibit myeloid dysplasia (including blasts, promyelocytes, myelocytes, or metamyelocytes) unlike in wild-type mice
|
|
• at 20 weeks
|
growth/size/body
|
• at 20 weeks
|
|
• at 20 weeks
|
